Member Info for LSBM

Sareum’s collaboration with Receptor.AI, announced in August 2025, was a short-term in-silico project expected to wrap up within four months, putting completion around December 2025. Perhaps a strong update is incoming that will inject some positivity into the investor meet.

I think we forget that Sareum hired a specialist US business development consultancy to support partnering discussions for assets like SDC-1801 and SRA737 that this is a proactive step rather than a sign of desperation. The consultancy was retained explicitly to accelerate value realisation through non-dilutive funding routes, such as partnerships or licensing deals, amid pipeline progress including optimised formulations for SDC-1801 (tox studies restarting Q1 2026) and improved economics on SRA737.
This aligns with Sareum’s stated priority of partnering for SDC-1802 and exploring options for SRA737 post-reacquisition, indicating active prospects rather than absence thereof.

Such hires are standard for clinical-stage biotechs like SAR to facilitate inbound/outbound discussions with big pharma, especially with near-term milestones (PK studies imminent, Receptor.AI collaboration on neuroinflammatory candidates).


Profit-taking after strong results is common for IAG, especially given high expectations, but recovery looks likely today, given the quality of the FY2025 beat and supportive analyst backdrop.

Fundamentals remain robust: €5bn+ operating profit (13% up, ahead of €4.7-4.9bn consensus), 15.1% margin (top of 12-15% guidance), €3.1bn FCF, leverage at 0.8x, and €1.5bn cash returns (€500m buyback + DPS hike).

Consensus leans bullish (16 buys/outperforms vs. 2 holds/sells as of mid-Feb), with targets implying 20%+ upside from recent 457p levels; historical post-results patterns show +4-10% rebounds within 1-2 days on similar beats.
Positive 2026 outlook (~3% capacity growth, -1% unit costs, FCF >€3bn) should draw buyers if FTSE holds firm, targeting 470-485p intraday on renewed volume.

I think it's recovering from the sell-out after the incidents. Don't forget the SP hit 360 when PoG was sub 5000. It's the overall sentiment, and of course, news will help.

Key Near-Term Catalysts

• Q1 2026 production update (late April): Expected to show continued Coringa ramp-up progress, with H2 weighted growth from higher plant feed grades post-ore sorter adjustments.

• March 2026 resource update: First cut from the ongoing 30k-meter exploration program, targeting a path to 1.3M ounces total resources (up from ~1M), validating longer-term 70-80k oz/year potential.

Great find and posts citizen.

Acrivon Therapeutics holds the exclusive worldwide rights to develop and commercialise prexasertib. Lilly licensed the asset to Acrivon in 2021 for up to $168M in milestones plus royalties, retaining a right of first negotiation to reacquire it. Acrivon, is actively developing prexasertib in Phase 2b/3 trials for ovarian, endometrial, and bladder cancers, with recent positive data and FDA fast-track designations. As of early 2026, no changes in ownership are reported, and Lilly retains milestone/royalty interests but no control.

Https://www.proactiveinvestors.co.uk/companies/news/1087822/raspberry-pi-shares-surge-as-super-small-openclaw-rival-goes-viral-on-social-media-1087822.html

Gains £10 and beyond as you know, this moves quickly.

The £5m secured convertible loan note facility from Alumni Capital LLC is a 12-month structured financing approved by TRLS shareholders on January 20, 2026.

Facility Duration and Tranches

Funds are drawn in tranches over 12 months from closing: first tranche £112,500 (net of fees), second up to £625,000 (27+ business days later), then up to £200,000 per subsequent tranche, conditional on prior conversions. All outstanding principal plus 2.5% p.a. interest is repayable 12 months from the facility date, with early conversion options at discounts (75% VWAP for most, 55% for second tranche).

Practical Runway Extension

Initial tranches extend cash runway to late Q1 2026 (March/April), bridging ~$400k/month burn from late January depletion, supporting commercial activities like the J&J extension. Full drawdown isn’t guaranteed (tranche conditions apply), and early termination triggers a 12% premium; partial conversions (e.g., £21k in Feb 2026) have already occurred.

Freddie, thanks for that post directly from Raspberry Pi: "Since these boards don’t use LPDDR4 memory, you can build an AI agent that’s insulated from supply constraints and price fluctuations in that market."

I think as the word gets out, this will start the upward movement. Most are assuming these products are linked to supply issues.

It’s not just Raspberry Pi—DRAM shortages are hitting the entire semiconductor industry hard due to AI data centre demand diverting supply, with LPDDR4 prices surging and high-density availability limited into 2026. RPI has already raised prices multiple times (e.g., Pi 5 8GB now £125, up £30), but as a value-oriented product with strong OEM demand (70% of sales) and inventory buffers, they can pass on costs more easily than premium competitors without losing volume. Shares dipped on uncertainty news but analysts predict upside from recent levels, not back to 250p anytime soon given solid 2025 EBITDA beat and H1 2026 supply secured.

A charting perspective for those who are interested: https://zakstraderscafe.com/bulletin-board-heroes-february-18-2/14307/

Got a mention on Zak's charting : https://zakstraderscafe.com/bulletin-board-heroes-february-18-2/14307/

Interesting that he thinks J&J contract not appreciated enough, notwithstanding the 100% rise!

Some huge buys going through 25000 shares @5.10

There are a few institutional investors:

Lansdowne Partners (UK) LLP

Hargreaves Lansdown Asset Management Limited

Legal & General Investment Management Ltd.

Baillie Gifford & Co.

Etc.

I meant 80.5% is locked up...

Float is 72m of which 80.5 is locked up with only 14.4m free from what I can make out. A lot of earlier trades are being reported to trigger stop losses. Traded over 4.1m already 10-day avg is around 500k.

Well, looks like this may have another leg up as the US wakes up.

The future is bright. Low market cap around £20 million, making it highly sensitive to positive revenue catalysts like pipeline conversion.

The company reports a qualified 2026/27 sales pipeline of £12.6 million, risk-weighted at £4.5 million, following 2025 revenues of £1.4 million (below prior £1.6 million guidance due to deferred contracts). Achieving even partial conversion—say, 50-70% of the risk-weighted value—could more than double annual revenues to £3-5 million, given the pivot to commercial execution and recent fundraising for balance sheet strength (£7.3 million cash end-2025).

At current valuations (price-to-sales ~1.2x, price-to-book 0.2x), full pipeline realisation could justify 2-4x upside to analyst targets (£0.17-0.37, consensus ~£0.28 from recent ~£0.07 levels), driven by margin expansion in liquid biopsy services. This assumes no major dilution; low mcap amplifies re-rating on revenue beats, though execution risks (timing, biopharma deals) cap near-term gains. As you know historical AIM biotech patterns show 50-200% pops on contract wins for similar profiles. It's only a matter of time.

Twice the 10-day average volume in the first hour of opening. Perhaps they have secured their DRAM supply, and we will get an RNS to de-risk further investment? Second-highest climber on the leaderboard today.

🚨 ImmuPharma’s P140: First-in-Class Immunormaliser Potential 🚨

P140 (Lupuzor) is first-in-class as it normalises upstream immune dysregulation (Type M endotype via CMA/autophagy & antigen presentation) without broad immunosuppression. Paired with a proprietary diagnostic for super-responder selection across ~50 autoimmune diseases.

Core MoA: 21-mer peptide restores homeostasis in APCs, cuts aberrant self-antigen MHC-II presentation → durable remission with clean safety. Distinct from immunosuppressants/biologics.

New Patent (Aug 2025): Covers Type M biomarker + P140 combo for precision therapy/dx. ~20yr exclusivity, de-risks trials via patient stratification. Lupus data solid; platform scope massive (>400M patients, $100B+ mkt).

Asset Value if Sold: Risk-adjusted NPV low-single to mid-single-digit $B range (1-5B headline deal potential). Lupus first, then basket expansion. Upfront likely $100sM + milestones/royalties; partnering talks ongoing into 2026. Benchmarks: early-mid stage autoimmune platforms.

TL;DR: Game-changing IP/platform story justifies multi-$B talk, but pre-Ph3 reality anchors at structured low-single-digit $B. DYOR and watch for deal news. 📈